News coverage about DexCom (NASDAQ:DXCM) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DexCom earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 46.1607740416658 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

A number of brokerages recently issued reports on DXCM. Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a report on Friday. Piper Jaffray Companies reaffirmed a “buy” rating on shares of DexCom in a report on Monday, March 12th. BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a report on Friday, March 9th. ValuEngine downgraded shares of DexCom from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. Finally, BMO Capital Markets increased their price objective on shares of DexCom to $74.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $65.97.

DXCM stock traded up $0.70 during trading hours on Friday, hitting $65.59. 904,783 shares of the stock traded hands, compared to its average volume of 1,052,686. The company has a current ratio of 5.36, a quick ratio of 5.04 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $5,706.13, a P/E ratio of -111.17 and a beta of 0.27. DexCom has a 12-month low of $42.62 and a 12-month high of $86.32.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.07. The firm had revenue of $221.00 million for the quarter, compared to the consensus estimate of $217.82 million. DexCom had a negative net margin of 6.99% and a negative return on equity of 13.99%. analysts expect that DexCom will post -0.56 earnings per share for the current year.

In other news, Chairman Terrance H. Gregg sold 10,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $55.91, for a total value of $559,100.00. Following the transaction, the chairman now directly owns 484,559 shares of the company’s stock, valued at $27,091,693.69. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard Doubleday sold 1,638 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $56.32, for a total transaction of $92,252.16. Following the completion of the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at $3,663,559.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,908 shares of company stock worth $1,401,535. Insiders own 1.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with's FREE daily email newsletter.